Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

Fineline Cube Sep 3, 2026
Company Deals PIC

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

Fineline Cube Sep 3, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Fineline Cube Sep 4, 2026
Company Drug

Ocumension Therapeutics and Shandong Boan Biotechnology File for Market Approval of Biosimilar Aflibercept in China

Fineline Cube Jul 17, 2024

Ocumension Therapeutics (HKG: 1477) and Shandong Boan Biotechnology Co., Ltd (HKG: 6955) have jointly announced...

Company Drug

Sino Biopharmaceutical’s Anlotinib Achieves Milestones in Phase III Trial for Soft-Tissue Sarcoma

Fineline Cube Jul 17, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced positive...

Company Deals

Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset

Fineline Cube Jul 17, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company

I-Mab Shakes Up Leadership with New Chairman and Interim CEO Appointments

Fineline Cube Jul 16, 2024

I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company, has announced significant changes to its leadership structure....

Company Medical Device

United Imaging Expands Latin America Footprint with Pediatric uMI 550 PET/CT Launch in Mexico

Fineline Cube Jul 16, 2024

United Imaging, a leading Chinese medical device manufacturer, has announced the launch of its uMI...

Company Deals

MGI Tech Partners with Predica Diagnostics to Advance RNA Sequencing in Cancer Detection

Fineline Cube Jul 16, 2024

MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has announced a...

Company Drug

Eli Lilly’s Lupus Treatment LY3361237 Misses Mark in Phase II Trial

Fineline Cube Jul 16, 2024

Eli Lilly & Co. (NYSE: LLY) has encountered a setback in its drug development pipeline...

Company Drug

BeiGene Receives NMPA Greenlight for BG-C9074 Clinical Trial in Advanced Solid Tumors

Fineline Cube Jul 16, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the National Medical Products Administration...

Company Drug

Celling Biotechnology’s CEL001 Earns Tacit Approval for Clinical Trials in China

Fineline Cube Jul 16, 2024

Celling Biotechnology Co., Ltd, a Guangzhou-based biopharmaceutical company, has announced that its pipeline candidate CEL001...

Company Drug

Sino Biopharmaceutical’s Rovadicitinib Gets CDE Nod for Review in Myelofibrosis

Fineline Cube Jul 16, 2024

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the Center for Drug Evaluation (CDE) in...

Company Drug

Sichuan Huiyu’s HY07121 Antifungal Protein Earns NMPA Review for Clinical Trials

Fineline Cube Jul 16, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese biopharmaceutical company, has announced that the...

Company Drug

Betta Pharmaceuticals’ EYP-1901 Implant Secures NMPA Clinical Trial Nod for Wet AMD

Fineline Cube Jul 16, 2024

Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from China’s...

Company Drug

Shenzhen Tyercan Bio-Pharma’s TYE1001 Earns Tacit IND Approval from FDA for Advanced Solid Tumors

Fineline Cube Jul 16, 2024

Shenzhen Tyercan Bio-pharm Co., Ltd, a biopharmaceutical company based in China, has announced that it...

Company Drug

Mabwell Bioscience Receives NMPA Approval for Phase II TNBC Clinical Trial of 9MW2821

Fineline Cube Jul 16, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that China’s National Medical Products Administration...

Company Deals

Lionco Pharmaceutical Partners with Laboratoire Bailly-Creat to Expand Overseas

Fineline Cube Jul 16, 2024

Shanghai-based Lionco Pharmaceutical Group (SHA: 603669) has entered into a strategic partnership framework agreement with...

Company Policy / Regulatory

Novo Nordisk Faces US Senators’ Scrutiny Over Levemir Withdrawal

Fineline Cube Jul 16, 2024

US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo...

Company

Johnson & Johnson Appoints Edward Zhou as Medtech China President

Fineline Cube Jul 16, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a global healthcare giant, has announced the appointment of...

Company Drug

Ipsen S.A. Receives NMPA Green Light for Six-Month Diphereline Dosage in Central Precocious Puberty

Fineline Cube Jul 16, 2024

Ipsen S.A. (EPA: IPN; OTCMKTS: IPSEY) has announced that it has received marketing approval from...

Company Drug

Shanghai HeartCare Medical Secures Taiwan Approval for Homegrown Femoral Artery Occluder

Fineline Cube Jul 16, 2024

Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609), a leading player in the Chinese medical...

Drug Legal / IP Policy / Regulatory

U.S. Senate Passes Affordable Prescriptions for Patients Act to Limit Patent Thicketing

Fineline Cube Jul 15, 2024

In a significant move to curb drug prices, the U.S. Senate unanimously passed the Affordable...

Posts pagination

1 … 380 381 382 … 716

Recent updates

  • MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
  • China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks
  • Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
  • Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
  • Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Company Drug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

Company Deals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.